Sygnature Discovery's TRPML drug discovery platform delivers comprehensive solutions for advancing TRPML1, TRPML2 and TRPML3 research. With advanced cell-based assay capabilities and a full suite of technologies, including fluorescence-based assays, solid-supported...
TRPML1 screening using solid supported membrane electrophysiology (SSME) provides a robust, high-throughput platform for profiling channel modulators. Sygnature Discovery applies this approach to accelerate early-stage discovery of TRPML1-tagreting therapeutic. ...
TRPML1 screening using automated electrophysiology provides a robust and efficient platform for ion channel drug discovery. Sygnature Discovery leverages this approach to support compound profiling, mechanism of action studies and lead optimization. Introduction...